Companies › Triveni Bio
2 active drug programs in 2 registered trials: 2 Phase 2; Immunology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TRIV-509 | – | Phase 2 | Atopic Dermatitis | Jun 2027 |
| TRIV-573 | – | Phase 2 | Atopic Dermatitis | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07167758 | TRIV-509 | Phase 2 | Atopic Dermatitis | Immunology | Jun 2027 |
| NCT07782333 | TRIV-573 | Phase 2 | Atopic Dermatitis | Immunology | Aug 2027 |
No annotated target.
–
MRM Health Citryll Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.